Efficacy of rapamycin and paclitaxel eluting stent implantation in treatment of coronary artery disease

doi:10.3969/j.issn.2095-4344.2015.52.027

Abstract

Abstract:

BACKGROUND: The clinical effect of drug-eluting stent implantation in treatment of coronary artery disease is good, but there may be some differences in the therapeutic effect between different stents.
OBJECTIVE: To compare the clinical effect of different stent implantation in treatment of coronary artery disease.
METHODS: A total of 278 patients with coronary artery disease were enrolled and all underwent coronary artery stent implantation treatment, of which 91 patients underwent implanted rapamycin eluting stent, 92 patients underwent implanted paclitaxel eluting stent, and 95 patients underwent implanted bare metal stents. All the patients were followed up for 12 months after stents implantation. The occurrence of adverse cardiac events such as death, myocardial infarction, and the occurrence of coronary restenosis and host reaction were recorded.
RESULTS AND CONCLUSION: The rates of coronary artery stenosis, acute myocardial infarction, coronary artery bypass grafting or second-time percutaneous coronary interventional therapy in the paclitaxel eluting stent and rapamycin eluting stent groups were all lower than those in the bare metal stent group (P < 0.05). There were no significant differences in the above indicators between paclitaxel eluting stent and rapamycin eluting stent
groups (P > 0.05). There was no significant difference in the mortality between these three groups (P > 0.05). There was no stent shift, shedding, breakage, bad implantation position, leukocytosis, thrombocytopenia and hemolysis in these three groups. These results demonstrate that the therapeutic effects of these two kinds of drug-eluting stents are all good enough, and better than those of bare metal stents.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

CLC Number:

R318

Yang Jun, Chen Dong-lin, Chen Yin-chao, Chen Xin-jing. Efficacy of rapamycin and paclitaxel eluting stent implantation in treatment of coronary artery disease [J]. Chinese Journal of Tissue Engineering Research, 2015, 19(52): 8517-8521.

Figures/Tables 4

References

[1] 彭育红,汝磊生,王冬梅,等.国产无聚合物紫杉醇微孔载药支架与雷帕霉素涂层支架对比治疗急性心肌梗死[J].介入放射学杂志, 2013,22(6):458-460.
[2] 王翔飞,钱菊英,刘学波,等.可降解聚乳酸涂层大黄素洗脱支架2年临床随访结果\曲尼司特洗脱支架对猪冠状动脉新生内膜增殖的影响[J].上海医学,2007,30(z1):33.
[3] 谢洪智,方全,张抒扬,等.冠状动脉长病变串联置入雷帕霉素和紫杉醇洗脱支架重叠部分对分支血管影响的比较[J].中华心血管病杂志,2008,36(6):497-500.
[4] Diletti R,Serruys PW,Farooq V,et al.ABSORB II randomized controlled trial: A clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design. Am Heart J.2012;164(5):654-663.
[5] 尹栋,窦克非,杨跃进,等.冠状动脉慢性完全闭塞病变置入FIREBIRD雷帕霉素洗脱支架和TAXUS紫杉醇洗脱支架长期有效性及安全性观察[J].中国循环杂志,2013,28(3):172-175.
[6] 赵杰,杨跃进,徐波,等.光学相干断层成像技术评价猪冠状动脉佐他莫司洗脱支架术后早期新生内膜覆盖情况[J].中国循环杂志, 2012,27(6):458-461.
[7] 邱洪,罗彤,胡小莹,等.新型生物可降解聚合物雷帕霉素靶向洗脱支架预防支架内狭窄的动物实验研究[J].中国循环杂志,2012, 27(3):220-223.
[8] 罗彤,高润霖,阮英茆,等.聚乳酸聚羟基乙酸共聚物涂层雷帕霉素洗脱支架对小型猪冠状动脉内膜增生的影响[J].中国循环杂志, 2008,23(6):459-462.
[9] 王哲颖,刘同库.雷帕霉素洗脱支架治疗无保护冠状动脉左主干严重狭窄性病变的安全性和远期效果研究[J].中国全科医学, 2013,16(27):3192-3195.
[10] 李强,王乐丰,杨新春,等.可降解涂层与不可降解涂层雷帕霉素洗脱支架在急性心肌梗死直接经皮冠状动脉介入治疗中的疗效比较[J].中华心血管病杂志,2010,38(10):886-890.
[11] Stone GW,Teirstein PS,Meredith IT,et al.A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.J Am Coll Cardiol. 2011;57(16):1700-1708.
[12] 金至赓,刘惠亮,张卓奇,等.血管内超声虚拟组织学成像评价可降解涂层雷帕霉素洗脱支架对冠状动脉壁的影响[J].中国循环杂志, 2012,27(1):13-16.
[13] 窦克非,徐波,杨跃进,等.TIVOLI完全可降解涂层西罗莫司洗脱支架与ENDEAVOR佐他莫司洗脱支架的临床随访结果[J].中国循环杂志,2012,27(5):334-337.
[14] 赵军礼,孙宝贵,温沁竹,等.三氧化二砷洗脱支架对犬冠状动脉支架术后内膜平滑肌细胞及Ⅲ型胶原的影响[J].中国中西医结合杂志,2010,30(6):636-639.
[15] 邓志华,袁勇,冯力,等.依维莫司洗脱支架与西莫罗斯洗脱支架治疗冠状动脉疾病随机临床对照试验的Meta分析[J].中国动脉硬化杂志,2013,21(5):463-467.
[16] 郝六一,程凌倩,张俊霞,等.经桡动脉应用改良Crush技术植入药物洗脱支架治疗冠状动脉分叉病变的疗效分析——附47例报告[J].新医学,2009,40(6):387-389.
[17] 郑勇.药物洗脱支架在糖尿病冠状动脉长病变中的应用研究[J].医学综述,2012,18(21):3682-3683.
[18] 沈雳,王齐兵,吴轶喆,等.完全可降解聚乳酸西罗莫司洗脱支架在小型猪冠状动脉模型中的实验研究[J].中国介入心脏病学杂志, 2011,19(6):301-305.
[19] 赵杰.光学相干断层成像评价猪冠状动脉药物洗脱支架置入后新生内膜覆盖的病理对比研究[D].北京协和医学院中国医学科学院,2012.
[20] 陈明,彭红玉,霍勇,等.一种新型可降解聚合物涂层-雷帕霉素洗脱支架对猪冠状动脉新生内膜增生的影响[J].心肺血管病杂志, 2010,29(4):333-337.
[21] 彭红玉,陈明,王皓正,等.聚丙交酯-乙交酯涂层-钴基合金雷帕霉素洗脱支架对猪冠状动脉新生内膜增生的影响[J].临床心血管病杂志,2008,24(5):341-345.
[22] 刘幼文,金光临,刘强,等.雷帕霉素洗脱支架治疗冠状动脉复杂病变的临床及冠状动脉造影随访观察[J].临床心血管病杂志, 2006, 22(7):426-428.
[23] 尹栋,窦克非,杨跃进,等.冠状动脉长病变患者置入雷帕霉素洗脱支架和紫杉醇洗脱支架2年临床观察[J].中国介入心脏病学杂志,2013,21(1):12-16.
[24] 赵军礼,孙宝贵,温沁竹,等.莪术油洗脱支架防治犬冠状动脉支架术后再狭窄的实验研究[J].中国中西医结合杂志, 2008, 28(4): 326-329.
[25] Sousa JE,Costa MA,Abizaid A,et al.Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries：a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 200l;103(2):192-195.
[26] Degertekin M,Serruys PW,Foley DP,et al.Persistent inhibition of neointimal hyperplasia after sirolimus.eluting stent implantation:long-term(up to 2 years)clinical,angiographic，and intmvascular ultrasound foIlow-up. Circulation. 2002; 106(13):1610-1613.
[27] Morice MC,Serruys PW,Sousa JE,et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.N Engl J Med. 2002; 346(23): 1773-1780.
[28] Babapulle MN,Joseph L,B61isle E, et al.A hierarchical Bayesian meta analysis of randomised clinical trials of drug-eluting stents.Lancet.2004;364(9434):583-59l.
[29] Farb A,Heller PE,Shroff S,et al.Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001;104(4):473-479.
[30] Giannakakou P,Robey R,Foio T,et al.Low concentrations of paclitaxel induce cell type-dependent p53,p2 l and G I,G2 arrest instead of mitotic arrest:molecular determinants of paclitaxel-induced cytotoxicity. Oncogene.2001;20(29): 3806-3813.
[31] Degertekin M,Serruys PW,Foley DP,et al.Persistent inhibition of neointimal hyperplasia after sirolimus．eluting stent implantation：long-term(up to 2 years) clinical, angiographic, and intmvascular ultrasound foIlow-up. Circulation. 2002; 106(13):1610-1613.
[32] Morice MC,Serruys PW,Sousa JE,et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.N Engl J Med. 2002; 346(23): 1773-1780.